title: [Cryptococcal meningitis disclosed by visual loss in HIV negative patient with ventriculo-atrial shunting].
abstract: BACKGROUND
  HIV infection is the main cause of cryptococcal neuromeningitis but other diseases may be associated with this infection.
  
  
  METHODS
  We report a case of cryptococcal neuromeningitis in a patient with sarcoidosis and ventriculoatrial shunting. The patient was successfully treated by effective therapy without device withdrawal.
  
  
  CONCLUSIONS
  The relationship between cryptococcosis and sarcoïdosis has been already described and may be not fortuitous. However it remains a very rare complication of sarcoidosis. Because of its potential severity (mortality rate of 40%), the diagnosis of cryptococcosis should be evoked as a differential diagnosis of neuro-sarcoidosis.
authors.affiliation: Service des Maladies Infectieuses et Tropicales, Hôtel-Dieu, CHU, 63000 Clermont-Ferrand, France.
authors.forename: X
authors.initials: X
authors.lastname: Gibold
authors.forename: A
authors.initials: A
authors.lastname: Husson
authors.forename: V
authors.initials: V
authors.lastname: Corbain
authors.forename: M
authors.initials: M
authors.lastname: Vidal
authors.forename: F
authors.initials: F
authors.lastname: Gourdon
authors.forename: H
authors.initials: H
authors.lastname: Laurichesse
authors.forename: J
authors.initials: J
authors.lastname: Beytout
authors.forename: P
authors.initials: P
authors.lastname: Irthum
authors.forename: A
authors.initials: A
authors.lastname: Ferrier
authors.forename: O
authors.initials: O
authors.lastname: Lesens
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001766:Blindness / Q000209:etiology*; D002557:Cerebrospinal Fluid Shunts / Q000379:methods*; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D015821:Eye Infections, Fungal / Q000150:complications*; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use; D005437:Flucytosine / Q000008:administration & dosage / Q000627:therapeutic use; D005438:Fludrocortisone / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D018023:HIV Seronegativity; D006801:Humans; D006849:Hydrocephalus / Q000150:complications / Q000628:therapy; D006854:Hydrocortisone / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D016919:Meningitis, Cryptococcal / Q000175:diagnosis* / Q000188:drug therapy; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D012507:Sarcoidosis / Q000134:cerebrospinal fluid / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000935:Antifungal Agents; D000666:Amphotericin B; D015725:Fluconazole; D011239:Prednisolone; D005437:Flucytosine; D005438:Fludrocortisone; D006854:Hydrocortisone